The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future?
Abstract
Current options for reperfusion therapy in patients admitted to a community hospital without cardiac catheterization facilities include administration of fibrinolytic drugs followed by observation, with referral to angiography driven by symptoms and signs of ischemia; transfer to a tertiary care center for primary percutaneous coronary intervention (PCI); or a strategy of facilitated PCI in which administration of fibrinolytics and platelet glycoprotein IIb/IIIa inhibitors (alone or in combination) is followed by transfer for immediate angiography and PCI if appropriate. We systematically analyzed multiple randomized and nonrandomized trials to review the pathophysiology of reperfusion therapy in acute myocardial infarction to derive insights about the likelihood of success of a strategy of facilitated PCI compared with transfer only or fibrinolysis only. The basis for the recommendations made herein is a hypothetical curve relating the duration of symptoms before reperfusion to reduction in mortality and extent of myocardial salvage. During the first 2 to 3 hours after symptom onset, a striking benefit of reperfusion is present; within this period, time to treatment is critical. Subsequently, a mortality benefit is still present but of decreasing magnitude over time. In this situation, the priority is to open the artery, and time to treatment is less critical. Results of facilitated PCI may depend largely on timing of presentation. If presentation is late after symptom onset (ie, on the "flat" part of the curve), there will be little mortality benefit from earlier patency and patients will be subject to the bleeding risks of fibrinolytic drugs. In contrast, among patients presenting very early (60-90 minutes after symptom onset), outcomes with fibrinolytic therapy alone are excellent, and it will be difficult for any other strategy to result in a significant improvement. But in patients presenting 2 to 3 hours after onset of symptoms, a strategy of facilitated PCI may move patients from the plateau to the descending limb of the curve, with a substantial improvement in myocardial salvage and mortality. Two large ongoing trials may provide definitive answers to these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12113-7 · Cited by 4,361
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
GRUPPOITALIANOPERLOSTUDIODELL (1986) · The Lancet · doi:10.1016/s0140-6736(86)92368-8 · Cited by 2,440
De Luca, G., Suryapranata, H., Ottervanger, J. P., & Antman, E. M. (2004) · Circulation · doi:10.1161/01.cir.0000121424.76486.20 · Cited by 1,542
Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour
Boersma, E., Maas, A. C., Deckers, J. W., & Simoons, M. L. (1996) · The Lancet · doi:10.1016/s0140-6736(96)02514-7 · Cited by 1,299
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone, G. W., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013404 · Cited by 1,277
Self-citationCannon, C. P. (2000) · JAMA · doi:10.1001/jama.283.22.2941 · Cited by 1,222
Reimer, K. A., & Jennings, R. B. (1979) · PubMed · Cited by 1,219
Gibson, C. M., Cannon, C. P., Murphy, S. A., Ryan, K. A., Mesley, R., Marble, S. J., McCabe, C. H., Van de Werf, F., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.2.125 · Cited by 858
Widimský, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00468-2 · Cited by 803
Weaver, W. D. (1993) · JAMA · doi:10.1001/jama.270.10.1211 · Cited by 685
Cited by
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective
Heusch, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0403-y · Cited by 1,234
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
Ibáñez, B., Heusch, G., Ovize, M., & Van de Werf, F. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.032 · Cited by 1,009
Clinical Features, Management, and Prognosis of Spontaneous Coronary Artery Dissection
Tweet, M. S., Hayes, S. N., Pitta, S. R., Simari, R. D., Lerman, A., Lennon, R. J., Gersh, B. J., Khambatta, S., Best, P. J. M., Rihal, C. S., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.105718 · Cited by 925
Self-citationFacilitated PCI in Patients with ST-Elevation Myocardial Infarction
Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Janssens, L., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706816 · Cited by 696
Metadata
- Authors
- Gersh, B. J., Stone, G. W., White, H. D., & Holmes, D. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-02-23
- Volume
- 293
- Issue
- 8
- Pages
- 979
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2050703343
- Cited by
- 439
- References
- 50
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? https://app.cochat.ai/papers/10.1001/jama.293.8.979
- The paper
- Gersh, B. J., Stone, G. W., White, H. D., & Holmes, D. R. (2005). Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? JAMA. https://doi.org/10.1001/jama.293.8.979
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.